Search results for " Humans"

showing 10 items of 2466 documents

Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Regist…

2019

BACKGROUND: We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. METHODS: Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T.…

Graft RejectionMalemedicine.medical_specialtyTime FactorsDrug Compoundingmedicine.medical_treatmentCalcineurin InhibitorsMedizinMEDLINEchemical and pharmacologic phenomenaLiver Transplant030230 surgeryLiver transplantationRisk AssessmentTacrolimusall contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA)03 medical and health sciences0302 clinical medicineRisk FactorsProlonged releaseInternal medicinemedicineHumansAged; Calcineurin Inhibitors; Delayed-Action Preparations; Drug Compounding; Europe; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Male; Middle Aged; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Tacrolimus; Time Factors; Treatment Outcome; Liver TransplantationRegistriesAgedRetrospective StudiesTransplantationbusiness.industryGraft SurvivalImmunosuppressionRetrospective cohort studyMiddle AgedTacrolimusSettore MED/18Liver Transplantation3. Good healthEuropeTreatment Outcomesurgical procedures operativeDelayed-Action PreparationsFemale030211 gastroenterology & hepatologyTransplant patientbusinessRisk assessmentImmunosuppressive AgentsTransplantation
researchProduct

Esfuerzos de participación de los profesores españoles exiliados en las conferencias internacionales por los derechos humanos y el nuevo orden intern…

2022

Este trabajo estudia la labor realizada por los profesores republicanos españoles exiliados en el movimiento por los derechos humanos y el nuevo orden mundial. La finalidad es investigar las posibles vías de participación en las reuniones que se celebraron, previas a la Declaración Universal de los Derechos Humanos de 1948. En particular, en la Conferencia de Chapultepec de 1945, a través del fondo histórico del Ateneo Español de México, donde se recoge la serie destinada a la Unión de Profesores Universitarios Españoles en el Extranjero (UPUEE) y el Boletín informativo de esta asociación. Para conocer si los profesores exiliados fueron o no actores en ese movimiento internacional por los d…

Guerra civilDrets humansExiliats
researchProduct

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage

2020

International audience; Intestinal microbiota have been proposed to induce commensal-specific memory T cells that cross-react with tumor-associated antigens. We identified major histocompatibility complex (MHC) class I-binding epitopes in the tail length tape measure protein (TMP) of a prophage found in the genome of the bacteriophage Enterococcus hirae Mice bearing E. hirae harboring this prophage mounted a TMP-specific H-2Kb-restricted CD8+ T lymphocyte response upon immunotherapy with cyclophosphamide or anti-PD-1 antibodies. Administration of bacterial strains engineered to express the TMP epitope improved immunotherapy in mice. In renal and lung cancer patients, the presence of the ent…

H-2 AntigenProgrammed Cell Death 1 ReceptorCD8-Positive T-LymphocytesEpitopeEpitopesFecesMice0302 clinical medicineEnterococcus hiraeNeoplasmsMonoclonalBacteriophages0303 health sciencesMultidisciplinarybiologyAntibodies MonoclonalViral Tail ProteinsAlkylating3. Good healthmedicine.anatomical_structure030220 oncology & carcinogenesisCross ReactionEpitopeImmunotherapyHumanT cellAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerCross ReactionsMajor histocompatibility complexAntibodiesMicrobiology03 medical and health sciencesAnimals; Antibodies Monoclonal; Antigens Neoplasm; Antineoplastic Agents Alkylating; Bacteriophages; CD8-Positive T-Lymphocytes; Cross Reactions; Cyclophosphamide; Enterococcus hirae; Epitopes; Feces; Gastrointestinal Microbiome; H-2 Antigens; Histocompatibility Antigens Class I; Humans; Immunotherapy; Mice; Neoplasms; Programmed Cell Death 1 Receptor; Viral Tail Proteins[SDV.CAN] Life Sciences [q-bio]/CancerAntigenAntigens NeoplasmMHC class ImedicineAnimalsHumansAntigensBacteriophageAntineoplastic Agents AlkylatingCyclophosphamideProphage030304 developmental biologyEnterococcus hiraeAnimalHistocompatibility Antigens Class IH-2 AntigensCD8-Positive T-Lymphocytebiology.organism_classificationGastrointestinal Microbiomebiology.proteinNeoplasmFeceCD8
researchProduct

Prophylaxis and treatment of hepatitis B in immunocompromised patients.

2007

The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunos…

HBsAgmedicine.medical_specialtyHepatitis C virusmedicine.medical_treatmentLiver transplantationTransplantmedicine.disease_causeGastroenterologyAntiviral AgentsImmunocompromised HostAnimals; Antiviral Agents; Carrier State; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Humans; Immunocompromised Host; Liver Transplantation; Tissue Donors; TransplantationAntivirals; HBV; Immunosuppression; Transplants;Internal medicineHBVMedicineAnimalsHumansAntiviralHepatitis B virusTransplantationHepatitis B Surface AntigensHepatologybusiness.industryGastroenterologyvirus diseasesHepatitis Bmedicine.diseaseHepatitis BHepatitis B Core Antigensdigestive system diseasesTissue DonorsLiver TransplantationTransplantationHBeAgImmunologyCarrier StateHepatitis D virusbusinessImmunosuppression
researchProduct

Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient dat…

2002

Background and aims: Retreatment with a combination of α interferon (IFN) plus ribavirin of patients with chronic hepatitis C who did not respond to IFN monotherapy has not been assessed in large controlled studies. Methods: To assess the effectiveness and tolerability of IFN/ribavirin retreatment of non-responders to IFN and to identify predictors of complete (biochemical and virological) sustained response, we performed a meta-analysis of individual data on 581 patients from 10 centres. Retreatment with various IFN schedules (mean total dose 544 mega units) and a fixed ribavirin dose (1000–1200 mg/daily depending on body weight) was given for 24–60 (mean 39.5) weeks. Results: Biochemical …

HCV interferon ribavirinAdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentAlpha interferonGastroenterologyAntiviral AgentsDrug Administration Schedulechemistry.chemical_compoundDrug TherapyInternal medicineRibavirinmedicineHumansImmunologic FactorsTreatment FailureChronicAdverse effectChemotherapyAdult; Antiviral Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy; Combination; Female; Hepatitis C; Chronic; Humans; Immunologic Factors; Interferon-alpha; Logistic Models; Male; Middle Aged; Ribavirin; Treatment Failure; gamma-GlutamyltransferaseChi-Square Distributionbusiness.industryRibavirinLiver DiseaseGastroenterologyInterferon-alphaHepatitis Cgamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CConfidence intervalhumanitiesSurgeryLogistic ModelschemistryTolerabilityCombinationDrug Therapy CombinationFemalebusiness
researchProduct

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

2018

Abstract Background & Aims Advances in direct‐acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked‐to‐care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030. Methods Using a modelling approach grounded in Italian real‐life data of diagnosed and treated patients, different linkage‐to‐care scenarios were built to evaluate potential strategies in achieving the HCV elimination goals. Results Under the 40% linked‐to‐care scenario, viraemic burden would decline (60%); however, eligible patients to treat w…

HCV; WHO; chronic infection; linkage to careLiver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularSustained Virologic ResponseViral HepatitisSettore MED/12 - GASTROENTEROLOGIAWorld Health OrganizationAntiviral AgentsNO03 medical and health sciencesLiver diseaseWHO0302 clinical medicinePharmacotherapyCost of IllnessCause of DeathHealth caremedicineHumans030212 general & internal medicineViremiachronic infection HCV linkage to care WHODisease EradicationMortalityIntensive care medicineCause of deathlinkage to carechronic infection; HCV; linkage to care; WHODisease EradicationHepatologybusiness.industryPublic healthCarcinomaLiver NeoplasmsHepatocellularHepatitis Cmedicine.diseasechronic infectionHepatitis CMarkov Chainschronic infection; HCV; linkage to care; WHO; Antiviral Agents; Carcinoma Hepatocellular; Cost of Illness; Disease Eradication; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Markov Chains; Mortality; Sustained Virologic Response; Viremia; World Health Organization; Cause of DeathItalychronic infection;HCV;linkage to care;WHOHCVchronic infection; HCV; linkage to care; WHO; Hepatology030211 gastroenterology & hepatologybusinessViral hepatitis
researchProduct

Perceptions of U = U Among Italian Infectious Diseases Specialists: A Nationwide Survey on Providers' Attitudes Toward the Risk of HIV Transmission i…

2022

This survey aimed to understand how far the Italian infectious diseases (ID) specialists are confident in the "Undetectable = Untransmittable" (U = U) message and translate this concept into clinical practice. An anonymous survey was distributed by e-mail to 286 clinicians to collect their opinions regarding six situations potentially at risk of HIV transmission between virologically suppressed patients and seronegative individuals who possibly require postexposure prophylaxis (PEP). Overall, 51% of ID specialists deemed zero risk of HIV transmission through condomless sex for undetectable patients. This answer was more frequent among HIV specialists (30% vs. 21%, p = .01) and clinicians wo…

HIV; HIV providers; PEP; U = U; survey; Humans; Surveys and Questionnaires; Attitude; RNA; Anti-HIV Agents; HIV Infections; PhysiciansSettore MED/17 - Malattie InfettiveAnti-HIV AgentsImmunologyAnti-HIV AgentHIVHIV InfectionsHIV providersInfectious DiseasesAttitudeSurveys and QuestionnairesPhysiciansVirologyPEPHIV providerSurveys and QuestionnaireHumansRNAHIV InfectionsurveyU = UHumanAIDS Research and Human Retroviruses
researchProduct

MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled tr…

2018

Introduction Masked uncontrolled hypertension (MUCH) carries an increased risk of cardiovascular (CV) complications and can be identified through combined use of office (O) and ambulatory (A) blood pressure (BP) monitoring (M) in treated patients. However, it is still debated whether the information carried by ABPM should be considered for MUCH management. Aim of the MASked-unconTrolled hypERtension management based on OBP or on ambulatory blood pressure measurement (MASTER) Study is to assess the impact on outcome of MUCH management based on OBPM or ABPM. Methods and analysis MASTER is a 4-year prospective, randomised, open-label, blinded-endpoint investigation. A total of 1240 treated hyp…

HYPERTENSION MANAGEMENTHipertensión.1302masked uncontrolled hypertensionEnfermedades cardiovasculares - Pacientes - Factores de riesgo.office blood pressureMASKED UNCONTROLLED HYPERTENSIONMedicina ClínicaCardiovascular Medicine030204 cardiovascular system & hematologyAMBULATORY BLOOD PRESSURE MONITORINGlaw.invention0302 clinical medicineClinical trialsRandomized controlled triallawBlood Pressure MonitoringMasked Hypertension//purl.org/becyt/ford/3.2 [https]ProtocolMulticenter Studies as Topic1506030212 general & internal medicineCardiovascular system - Diseases - Patients - Risk factors.Blood pressure.OFFICE BLOOD PRESSURERandomized Controlled Trials as TopicSistemas Cardíaco y CardiovascularGeneral MedicineBlood Pressure Monitoring Ambulatory3. Good healthCor MalaltiesEchocardiographyAmbulatoryHypertensionBlood pressure//purl.org/becyt/ford/3 [https]Hipertensióambulatory blood pressure monitoring; hypertension; hypertension management; masked uncontrolled hypertension; office blood pressure; treated hypertensive patientsTREATED HYPERTENSIVE PATIENTS1683medicine.medical_specialtyAmbulatory blood pressureCIENCIAS MÉDICAS Y DE LA SALUDhypertensionHeart Ventriclestreated hypertensive patientPressió sanguínia03 medical and health sciencesAmbulatoryHypertension.medicineAlbuminuriaHumansAntihypertensive AgentsProtocol (science)business.industryConsolidated Standards of Reporting Trialsambulatory blood pressure monitoring; hypertension; hypertension management; masked uncontrolled hypertension; office blood pressure; treated hypertensive patients; Albuminuria; Antihypertensive Agents; Echocardiography; Heart Ventricles; Humans; Masked Hypertension; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Blood Pressure Monitoring Ambulatorytreated hypertensive patientsambulatory blood pressure monitoringBlood pressurePresión sanguínea.Good clinical practiceEmergency medicinebusinessDeclaration of Helsinkihypertension managementAssaigs clínicsBMJ Open
researchProduct

Sentieri: mortality, cancer incidence and hospital discharges. Summary

2014

Hazardous Wastecancer incidenceIncidenceSettore MED/42 - Igiene Generale E ApplicataPatient DischargeEnvironmental Monitoring; Environmental Pollution; Epidemiological Monitoring; Hazardous Waste; Humans; Incidence; Italy; Neoplasms; Patient Admission; Patient Discharge; Population Surveillancehospital dischargePatient AdmissionItalycancer incidence; hospital discharge; cancer mortalityNeoplasmsPopulation SurveillanceEpidemiological Monitoringcancer mortalityHumansEnvironmental PollutionEnvironmental Monitoring
researchProduct

The Health Risks of Electronic Cigarettes Use in Adolescents

2020

The evidence to date suggests that vaping is not a safe alternative to smoking tobacco. This, coupled with the worrying trend of young nonsmokers being attracted to vaping, raises fears of yet another generation suffering from chronic lung disease and other acute and chronic health conditions. Finally, due to the insufficient regulations in several countries, up-to-date data on the prevalence of e-cigarette use and studies on the health's implications of their use are urgently needed to inform policy at a national and international level (ie, European Union). Pediatricians are typically on the front line for identifying emerging risks for children and adolescents ; therefore, they may effec…

HealthRisk Electronic Cigarette AdolescentsAdolescentbusiness.industryVapingAdolescent ; Electronic Nicotine Delivery Systems ; Humans ; Risk Factors ; VapingElectronic Nicotine Delivery Systemscigarettes childrenchildrenSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICARisk FactorsEnvironmental healthPediatrics Perinatology and Child HealthHumansMedicinebusinesscigarettesThe Journal of Pediatrics
researchProduct